Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LOX | P28300 | 1/20 | 0.30 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.30 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27906075 | 0.88 | — | — | |
| SCHEMBL365120 | 0.79 | — | — | |
| SCHEMBL28802451 | 0.79 | TSHR (0.55) | TSHRALDH1A1TDP1CYP3A4MAPT | |
| SCHEMBL20494560 | 0.78 | — | — | |
| SCHEMBL2568120 | 0.78 | — | — | |
| SCHEMBL2565575 | 0.78 | — | — | |
| SCHEMBL645518 | 0.78 | ALDH1A1 (0.58) | TSHRALDH1A1TDP1CYP3A4MAPT | |
| SCHEMBL1004069 | 0.78 | ALDH1A1 (0.58) | TSHRALDH1A1TDP1CYP3A4MAPT | |
| SCHEMBL411130 | 0.78 | ALDH1A1 (0.58) | TSHRALDH1A1TDP1CYP3A4MAPT | |
| SCHEMBL5203287 | 0.78 | ALDH1A1 (0.58) | TSHRALDH1A1TDP1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2276759-B1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | LILLY CO ELI (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7932274-B2 | 3-indazolyl-4-pyridylisothiazoles | ELI LILLY AND COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2276759-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | Eli Lilly & Company (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20090253750-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | ELI LILLY AND COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009123855-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | ELI LILLY AND COMPANY (US) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253750-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | CYP3A4, IPO4, JAK3 | TSHR 2970/4885ALDH1A1 853/4885TDP1 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.